Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The study aims to assess antineoplastic efficacy, safety, influence on quality of life and
disease-related stress of propranolol taken in combination with sunitinib in previously
untreated metastatic renal cell carcinoma